Oxis Turbohaler 6 (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate, the active ingredient in Oxis Turbohaler 6, is a long‑acting β2‑adrenergic agonist presented as a dry‑powder inhaler for inhalation use. It provides bronchodilation for patients with reversible airway obstruction, typically in asthma and chronic obstructive pulmonary disease. GNH USA supplies Oxis Turbohaler 6 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oxis Turbohaler 6 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Formoterol fumarate dihydrate is a bronchodilator that acts on the β2‑adrenergic pathway to relax airway smooth muscle. - Asthma: improves control of symptoms and reduces the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): provides sustained bronchodilation and helps decrease dyspnoea during daily activities. - Exercise‑induced bronchoconstriction: prevents airway narrowing that can occur with physical exertion.

Formoterol may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Throat irritation: mild discomfort or dryness in the throat after inhalation. - Cough: transient coughing immediately after use of the inhaler. - Headache: mild to moderate headache not related to other causes. - Tremor: fine shaking of the hands, especially at higher doses. - Palpitations: sensation of rapid or irregular heartbeat.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of airway obstruction after inhalation. - Cardiac arrhythmia: irregular heart rhythm that may require medical attention. - Hypokalaemia: low blood potassium levels, potentially leading to muscle weakness. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Hyperglycaemia: elevated blood glucose, particularly in patients with diabetes.

When using Formoterol inhalation therapy, patients and clinicians should observe several safety measures. - Assess severity: evaluate the patient’s baseline lung function before initiating therapy. - Monitor response: regularly review symptom control and rescue‑inhaler use. - Avoid overuse: do not exceed the prescribed number of inhalations per day. - Caution in cardiac disease: patients with known arrhythmias or coronary disease should be monitored closely. - Pregnancy and lactation: use only if the potential benefit outweighs any risk to the fetus or infant. - Store at ambient temperature: keep below 25°C, in the original packaging, protected from moisture and direct sunlight.

Formoterol may interact with several other medicines, altering its safety or effectiveness.

Major Interactions (Avoid):\n- Non‑selective β‑blockers: may diminish bronchodilator response and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): can increase the risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate hypokalaemia when combined with β2‑agonists. - Theophylline: concurrent use can increase the likelihood of tremor and tachycardia. - Corticosteroids: may enhance systemic β2‑agonist effects, requiring dose adjustment. - Anticholinergics: additive bronchodilation may increase the risk of dry mouth. - Certain antidepressants (e.g., SSRIs): may potentiate tachycardia, requiring observation.